Condition: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Mixed Lineage Acute Leukemia · Sponsor: Syndax Pharmaceuticals
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
This description comes directly from the study's public registry record.
Syndax Pharmaceuticals · 781-419-1400 · clinicaltrials@syndax.com
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Active Not Recruiting |
| University Of California Care Medical Group - Norris Comprehensive Cancer Center And Hospital | Los Angeles, California, United States | Completed |
| Stanford Cancer Institute | Palo Alto, California, United States | Active Not Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Florida Cancer Specialists and Research Institute | Sarasota, Florida, United States | Active Not Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Completed |
| Emory Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Completed |
| The University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| University of Iowa Hospital | Iowa City, Iowa, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Active Not Recruiting |
| Washington University in St. Louis School of Medicine | St Louis, Missouri, United States | Recruiting |
+ 45 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04065399